Mini Review

Treatment of Rectal Cancer with Trans-Anal Mesorectal Excision: A Mini-Review of the Literature

Abstract

Background: The aim of this mini-review is to summarize the body of literature based on studies on the perioperative and oncological outcomes of transanal total mesorectal excision (TaTME) for the treatment of rectal cancer.

Methods: A literature search of PUBMED database was performed using subject headings and keywords related to rectal adenocarcinoma and transanal mesorectal excision.

Results: Five case series were identified, reporting on a total of 378 patients with mean/median age ranging from 56.5 to 67.6 years and body mass index ranging from 25.2 to 27.5 kg/m². The mean/median operative time was 166 to 270 minutes. Conversion rate to open approach ranged from 0% to 7.3% whereas post-operative complication rate ranged from 26% to 39%. The length of stay ranged from 4.5 to 10 days. The completeness of circumferential resection margin (CRM) was reported to be between 72% to 97.1%. CRM positivity ranged from 2.5% to 6.4%. The distal resection margin (DRM) ranged from 10 mm to 37.1 mm and DRM positivity ranged from 0% to 2%. The mean/median lymph node harvested ranged from 12 to 20. Short-term oncological outcome (median follow-up period of 15.1 to 29 months) was reported with local recurrence rate from 1.9% to 4% and distal recurrence rate of 3.9% to 14.5%.

Conclusions: TaTME appears to be a safe technique for treatment of rectal cancer although the current evidence is limited by the heterogeneity of the quality of available studies. Randomized control trials would be necessary to assess the long-term safety and oncological outcomes of TaTME as compared to conventional rectal surgery techniques.

Keywords: Transanal total mesorectal excision; Transanal surgery; Minimally invasive surgery; Rectal cancer; Laparoscopic rectal surgery; Systematic review

Introduction

Total mesorectal excision (TME) during open abdominal surgery has become the gold standard treatment for middle and lower rectal cancers [1]. First described by Heald et al. [1], in 1982, TME involves en bloc resection of rectal tumor and mesorectum [1,2]. TME decreases locoregional recurrence rates and increases overall survival after rectal cancer surgery [3]. Recent improvements in technology have had significant effects on how surgeons perform TME with an increasing interest in minimally invasive approaches. Laparoscopic TME (LapTME) has been shown by many randomized control trials (including COLOR II, COREAN, and CLASICC) to offer comparable clinical outcomes in terms of complications and oncological outcomes as compared to open TME [4-7]. Other studies have shown LapTME to be associated with less blood loss, shorter hospital stay, earlier return of bowel function, and fewer wound infections [5,8,9]. LapTME may still be challenging in patients with unfavorable traits including low rectal tumors, narrow pelvic anatomy, male sex or high body mass index (BMI). Difficult visualization of the pelvic anatomy along with the limitation of rigid laparoscopic
Instruments may affect the quality of resection margins and increase the risks of neurovascular injuries during surgery. Two randomized trials (AlCaRT and ACOSOG Z6051) demonstrated that laparoscopic rectal surgery did not meet non-inferiority for oncological resection quality when compared to the classic open approach [10,11]. However, conversion rate from laparoscopic to open TME surgery was as high as 34% [12-14].

In an effort to address these limitations associated with LapTME, a novel concept of “down to up” transanal TME (TaTME) has been proposed by several authors Sylla, De lacy, Heald [15-17]. The concept of TaTME has become a reality because of the improvements of transanal abdominal proctosigmoidectomy (TATA), transanal endoscopic microsurgery (TEMS), transanal minimally invasive surgery (TAMIS), and natural orifice transluminal endoscopic surgery (NOTES) [18-20]. TATA was introduced in 1984 by Marks et al. [19]. By starting transanally and establishing a safe distal resection margin (DRM) as a first step, Marks et al. were able to perform more sphincter preserving surgeries and decrease the need for permanent colostomies [19]. TEMS approach was introduced in 1984 by Buess et al. [18,21], and involves excision of rectal lesions using an operating proctoscope, endoluminal insufflations, and specialized endoscopic instruments used within pneumorectum [18,21]. TEMS allows access to the middle and the upper rectum (up to 20 cm from the anal verge). A full thickness rectal wall excision can be made to remove the rectal tumor and the defect can be left open or sutured closed. TAMIS is a similar technique to TEMS but it involves a use of low-cost single incision laparoscopic port and standard laparoscopic instruments [22,23]. NOTES allows surgical procedure through natural orifices via transgastric, transvaginal or transrectal approach. In 2007, Whiteford et al. [24] described the feasibility of performing rectosigmoidectomy via transanal route using TEMS platform on a human cadaver. Since then, numerous animal and human cadaver studies have illustrated safety and feasibility of TaTME [20,25-28]. In 2010, the first clinical case report of TaTME using TEMS with laparoscopic assistance was published by Sylla et al. [20]. Furthermore, TaTME approach has been applied outside the setting of rectal cancer including completion proctectomy in patients with inflammatory bowel disease and reversal of Hartmann’s procedure [29,30].

The aim of this mini-review is to summarize the body of literature based on studies looking at the safety and feasibility of TaTME for the treatment of rectal cancer. TaTME is a technique that requires expertise in both laparoscopic rectal surgery and TEMS/TAMIS techniques. Case reports and small case series may reflect outcomes during the early learning phase and may not truly reflect the whole spectrum of complication rate and oncological outcomes following TaTME surgery. In order to mitigate this, our review study focused only on larger case series that involved 50 or more participants. The peri-operative outcomes, histopathological results, and short-term oncological outcomes will be presented. Lastly, the key potential benefits and limitations of TaTME technique will be discussed.

Surgical techniques highlights

The procedure is performed using two main techniques; laparoscopic-assisted TaTME or NOTES TaTME, and Pure TaTME [31-34]. Laparoscopic-assisted TaTME includes two surgical fields, abdominal and transanal. A one-team approach involves sequential phases, where either abdominal or transanal dissection is performed first. TaTME can also be performed by two surgical teams working simultaneously; one team performs the abdominal dissection while the other team performs the transanal part.

The essential steps of laparoscopic-assisted TaTME are: (1) Insertion of transanal platform (TEMS or SILS port) and the creation of pneumorectum, (2) Occlusion of rectum distal to the rectal lesion via purse string, (3) Transanal dissection of lower and mid rectum mesorectal, (4) Abdominal approach with laparoscopic mobilization of the left colon and if required of the splenic flexure, (5) Laparoscopic isolation and transection of inferior mesenteric vessels, (6) Transabdominal dissection of the upper rectum mesorectal, (7) Joining of abdominal and transanal surgical fields, (8) Completion of the anterior resection and removal of specimen, and (9) Creation of colorectal or coloanal anastomosis.

The transanal phase begins with the insertion of a single-port device, commonly with either SILS port or TEMS platform. From here, the tumor can be visualized and purse string suture is performed 1 cm to 5 cm below the distal tumor margin, depending on the location of the tumor in relation to the anal sphincter. Application of purse string will prevent spillage of bowel content as to minimize bacterial infection and prevent possible tumor cell spillage during surgery. Distal to the purse string, full thickness rectal wall dissection is made to gain entry into the perirectal space. The ability to clearly identify the distal resection margins at the beginning of surgery is a key feature of TaTME. This is thought to improve oncological resection margin quality and increase the chance for sphincter preservation. Next, a mesorectal excision is performed from distal to proximal direction. Careful consideration is made not to breach the rectoprostatic/rectovaginal fascia or the mesorectal fascia. The surgeon must be cognizant of the curvature of the sacrum as well as the presence of neurovascular structures on the lateral sides. Posterior dissection, if performed too deep beyond the presacral space, can lead to injury of the sacral venous plexus leading to significant blood loss.

The specimen can be extracted through an abdominal incision through the ileostomy site, mid-line incision, or Pfannenstiel incision. In patients with a small rectal tumor or non-bulky mesorectum, the specimen can also be removed transanally. This approach would theoretically decrease the risk of an incisional hernia after TaTME as compared to open surgery.

NOTES TaTME or Pure TaTME does not involve an abdominal incision, instead, the entire procedure is performed transanally with a “down to up” approach and the specimen is extracted via the anus [34,35].
The colorectal anastomosis is generally performed using a circular stapler or the EEA™ hemorrhoid stapler. For resection of very low rectal cancer, a hand-sewn coloanal anastomosis is often preferred. There have been four different anastomotic techniques that have been described in an excellent paper by Penna et al. [36].

Methods

Search strategy
A comprehensive search of the PubMed database was performed using the following subject heading and keywords: rectal neoplasm, adenocarcinoma, rectum, treatment outcome, adult, mesorectal, transanal endoscopic microsurgery, transanal endoscopic surgery, TaTME, complications and outcomes.

Inclusion and exclusion criteria
Prospective or retrospective clinical case studies on patients affected by rectal adenocarcinomas undergoing mesorectal excision were included. Exclusion criteria were: case reports, systematic reviews, meta-analysis, studies on patients affected by recurrent rectal cancers, patients younger than 18 years, treatment of benign rectal tumors or other malignancies such as melanomas, neuroendocrine tumors, gastrointestinal stromal tumors, sarcomas or other non-epithelial malignancies. Studies comparing TaTME to LapTME, duplicate studies and scientific papers in languages other than English were also excluded (Figure 1) [37]. The references of each included study were examined to ensure additional studies were not overlooked. Each reference was manually retrieved from PubMed and its abstract reviewed. No additional studies were identified from assessing the reference of included study.

Data collection
Data retrieved from each included study were: first author’s last name, year of publication, total number of participants, patient demographics (age, BMI, gender, ratio, the American Society of Anesthesiologist (ASA) status, and neoadjuvant therapy), perioperative details (operative time, operative team approach, type of abdominal assistance, type of transanal platform, conversion to open surgery, and intraoperative complications, postoperative complications, length of stay), histopathological outcomes (circumferential resection margin (CRM) quality/positivity, distal resection margin (DRM) margin/positivity, and number of lymph node harvested), and short-term oncological outcomes (follow-up period, local recurrence and distal recurrence).

Figure 1 Flowchart representing the inclusion and exclusion of studies using preferred reporting items for systematic reviews and meta-analyses (PRISMA).
Results

Patient demographics

In total, 378 patients underwent TaTME (Table 1) [33,38-41]. The study from Lacy et al. presented the largest homogeneous single-center prospective study with 140 patients [38]. With exception of one patient diagnosed with a large sessile villous adenoma (>8 cm) with multiple foci of adenocarcinoma in situ, the rest of the study population had rectal adenocarcinomas. The age of the patients ranged from 35 to 87 years. The overall male to female ratio was 1.6:1. The mean/median BMI ranged from 25.2 to 27.5 (range, 19.4 to 42). The majority of patients were ASA class II. The neoadjuvant therapy varied from different studies ranging from 33.3% to 86%. Overall, 285 out of 378 patients (75.4%) underwent neoadjuvant therapy.

Intraoperative characteristics

The majority of patients who had abdominal assistance were operated using laparoscopic multi-ports (Table 2). TaTME was mainly performed with TAMIS platform via GelPOINT Path transanal platform or SILS port. The mean/median operative time ranged from 166 to 270 minutes (range, 60 to 495). Of the 378 patients included in this review, 8 patients (2.1%) required conversion to open surgery. The reasons for conversion included fixation of the anterior rectum to adjacent structures, intra-op cardiac complications, severe intra-abdominal adhesions, and technical difficulty due to obesity (BMI=32 and 37), and locally advanced tumors causing concern for the resection margin status. The mean/median length of stay varied between 4.5 to 10 days (range 3 to 41). In total, 8 cases (2.1%) of intra-operative complications were reported. Veltcamp Helbach et al. [40] reported 5 cases with 2 cases of hemorrhage and 3 cases of complications were reported. Burke et al. [41] reported 5 cases with 2 cases of hemorrhage and 3 cases of rectal perforation that required repair with transanal suturing. Burke et al. [41] reported 3 intra-operative complications (two urethral injuries and one internal iliac vessel injury). Out of these 3 injuries, only one case of urethral injury occurred during the transanal phase. Amongst included studies, the rate of post-operative complications ranged from 26% to 39%. Most commonly described post-operative complications included anastomotic leak, intraabdominal/pelvic abscess, ileus/bowel obstruction, and urinary retention/infection. Three out of five studies summarized in this review reported their complications using Clavien-Dindo (CD) classification (Table 3) [33,38,40,42]. Minor complications (CD classification I and II) ranged from 15.7% to 26.3%, whereas major complications (CD classification III+V) ranged from 10% to 15.7%. Overall, there were 3 cases (0.8%) of postoperative mortality (CD classification V). One case of mortality, reported by Veltcamp Helbach et al. [40], was due to severe sepsis from an anastomotic leak. Two cases of mortality were reported by Huscher et al. [33], where one patient passed away from a pulmonary embolism and another patient had an acute peritonitis leading to death from multi-organ failure.

Outcomes

Histopathological and oncological outcomes are reported in Table 4. The quality of CRM was graded according to Quirke classification in complete, near incomplete or incomplete (Table 5) [43]. Complete CRM was reported in 72% to 97.1% of patients. Positive CRM ranged from 0% to 6.4%. DRM resection margin ranged from mean/median value of 10 mm to 37.1 mm. Three out of 5 studies reported DRM positivity status. The only positive DRM was observed in 1 patient [41]. The mean/median numbers of lymph node harvested were 12 to 20 (range 6 to 30). The oncologic outcomes were reported by 4 out of 5 studies. The median follow-up period ranged from 15.1 to 29 months (range, 1-52 months). Local recurrence was observed in the range of 1.9% to 4% of patients and distal recurrence rate ranged from 3.9% to 14.5%. The survival outcomes were quantified by 2 away from a pulmonary embolism and another patient had an acute peritonitis leading to death from multi-organ failure.

Discussion

Several technical challenges are associated with laparoscopic treatment of distal rectal tumors in patients with narrow pelvis or obesity. Limited visualization and insufficient maneuverability preclude safe dissections and the appropriate firing of laparoscopic staples leading to conversion to open surgery.

Table 1. Summary of clinical characteristic of the patient populations of all studies included in this mini review.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>N</th>
<th>Age (range)</th>
<th>Gender</th>
<th>BMI (Range)</th>
<th>ASA Class (%)</th>
<th>Neoadjuvant Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lacy et al. [38]</td>
<td>2015</td>
<td>140</td>
<td>65.5 +/- 12.7*</td>
<td>89: 51</td>
<td>25.2 +/- 3.9*</td>
<td>1-8 (5.7)</td>
<td>CRT: 90 (64.2) Chemo 3 (2.1) RT -1 (0.7)</td>
</tr>
<tr>
<td>Huscher et al. [33]</td>
<td>2016</td>
<td>102</td>
<td>67.6 (35-87)</td>
<td>56: 46</td>
<td>25.3 +/- 4.1*</td>
<td>1-3 (2.9)</td>
<td>CRT: 34 (33.3)</td>
</tr>
<tr>
<td>Helbach et al. [40]</td>
<td>2016</td>
<td>80</td>
<td>66.5 (42-86)</td>
<td>48: 32</td>
<td>27.5 (19.4-40)</td>
<td>1-15 (18.8)</td>
<td>CRT: 67 (83.8) RT: 26 (32.5) RT: 39 (48.8)</td>
</tr>
<tr>
<td>Tuch et al. [39]</td>
<td>2015</td>
<td>56</td>
<td>65+ (39-83)</td>
<td>41: 15</td>
<td>27+ (20-42)</td>
<td>1-5 (8.9)</td>
<td>CRT: 47 (83.9)</td>
</tr>
<tr>
<td>Burke et al. [41]</td>
<td>2015</td>
<td>50</td>
<td>56.5 (50-65)</td>
<td>30: 20</td>
<td>26.0 (22.7-31.2)</td>
<td>I/II 36 (72)</td>
<td>CRT: 43 (86)</td>
</tr>
</tbody>
</table>

N: Number of participants; m:f: Male to female ratio; BMI: Body mass index; ASA: The American Society of Anesthesiologists; CRT: Chemoradiation therapy; Chemo: chemotherapy; RT: Radiation therapy

*Mean +/- standard deviation

*Median value

This article is available in: http://colorectal-cancer.imedpub.com/archive.php
Table 2. Summary of TaTME clinical cases: operative characteristics, postoperative complications and hospital length of stay.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>N</th>
<th>Operative Time</th>
<th>Operative Team</th>
<th>Abdominal Assistance</th>
<th>Transanal platform</th>
<th>Conversion Rate n (%)</th>
<th>Intraoperative Complications (%)</th>
<th>Post-operative Complication Clavien-Dindo (%)</th>
<th>Post-operative complication</th>
<th>Length of Stay, days (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lacy et al. [38]</td>
<td>2015</td>
<td>140</td>
<td>166 +/-57*</td>
<td>Two-team</td>
<td>Multi-port</td>
<td>GelPOINT Path Transanal</td>
<td>0</td>
<td>0</td>
<td>48 (34.3)</td>
<td>I/II - 34 (24.2) III/IV - 14 (10)</td>
<td>V - 0 (0)</td>
</tr>
<tr>
<td>Huscher et al. [33]</td>
<td>2016</td>
<td>102</td>
<td>185 (60-480)</td>
<td>Single-team</td>
<td>Multi-port</td>
<td>GelPOINT path transanal, SILS port, or TEM rectoscope</td>
<td>0</td>
<td>0</td>
<td>34 (33.3)</td>
<td>I/II - 16 (15.7) III/IV - 16 (15.7)</td>
<td>V - 2 (1.9)</td>
</tr>
<tr>
<td>Veltcamp Helbach et al. [40]</td>
<td>2016</td>
<td>80</td>
<td>204 (91-447)</td>
<td>Single-team</td>
<td>Multi-port or Single-port</td>
<td>GelPOINT Path Transanal or SILS port</td>
<td>4 (5)</td>
<td>Hemorrhage -2 Rectal perf - 3</td>
<td>31 (39)</td>
<td>I/II - 21 (26.3) III/IV - 9 (11.3)</td>
<td>V - 1 (1.3)</td>
</tr>
<tr>
<td>Tuech et al. [39]</td>
<td>2015</td>
<td>56</td>
<td>270* (150-195)</td>
<td>NR</td>
<td>Multi-port or Single-port</td>
<td>GelPOINT Path transanal, or endorectal TUC or TEP</td>
<td>3 (7.3)</td>
<td>0</td>
<td>14 (26)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Burke et al. [41]</td>
<td>2015</td>
<td>50</td>
<td>267* (227-331)</td>
<td>Two-team or Single-team</td>
<td>Open, Laparoscopic or Robotic</td>
<td>GelPOINT Path Transanal</td>
<td>1 (2.2)*</td>
<td>Urethral injury - 2 Internal iliac vessel injury - 1</td>
<td>(36)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

N: number of participants; NR: not reported
*Mean +/- standard deviation; *Median value; *Total number of patient 46, as 4 patients had planned open surgery wit TaTME; One urethral injury occurred during transanal phase.

Table 3. Clavien-Dindo classification for postoperative complications [42].

I Any deviation from the normal post-operative recovery without the need for pharmacological treatment
II Complications requiring pharmacological treatment
III Complications requiring radiological, endoscopic or surgical intervention
IV Life-threatening complications requiring ICU care
V Complications resulting in Death

Table 4. Summary of TaTME clinical cases: histopathological characteristics and oncological outcomes.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>N</th>
<th>CRM Quality %</th>
<th>CRM Positivity %</th>
<th>DRM mm (range)</th>
<th>DRM Positivity %</th>
<th>Lymph node harvested (range)</th>
<th>Median Follow up period, months (range)</th>
<th>Local Recurrence (%)</th>
<th>Distal Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lacy et al. [38]</td>
<td>2015</td>
<td>140</td>
<td>Complete: 97.1</td>
<td>6.4*</td>
<td>28 +/-2.1*</td>
<td>0</td>
<td>14.7 +/-6.8*</td>
<td>15.1 (7-20)*</td>
<td>3 (2.3)</td>
<td>10 (7.6)</td>
</tr>
<tr>
<td>Huscher et al. [33]</td>
<td>2016</td>
<td>102</td>
<td>Complete: 97.1</td>
<td>5.4*</td>
<td>37.1 +/-28.5*</td>
<td>0</td>
<td>20 +/-11.7*</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Veltcamp Helbach et al. [40]</td>
<td>2016</td>
<td>80</td>
<td>Complete: 88</td>
<td>2.5*</td>
<td>NR</td>
<td>NR</td>
<td>14 (6-30)</td>
<td>NR</td>
<td>2 (2.5)</td>
<td>0</td>
</tr>
<tr>
<td>Tuech et al. [39]</td>
<td>2015</td>
<td>56</td>
<td>Complete: 84</td>
<td>5.4*</td>
<td>10 (3-40)</td>
<td>NR</td>
<td>12 (7-29)</td>
<td>29 (18-52)</td>
<td>1 (1.9)</td>
<td>2 (3.9)</td>
</tr>
<tr>
<td>Burke et al. [41]</td>
<td>2015</td>
<td>50</td>
<td>Complete: 72</td>
<td>4*</td>
<td>10 (5-17)</td>
<td>2</td>
<td>18 (12-23.8)</td>
<td>15.1 (9.7-20.4)</td>
<td>2 (4)</td>
<td>7 (14.5)*</td>
</tr>
</tbody>
</table>

N: Number of participants; NR: Not reported; CRM: Circumferential resection margin; DRM: Distal section margin
*Mean +/- standard deviation; *Positive if tumor cells within 1mm from the CRM; *Positive if tumor cells within 2 mm from the CRM; *Total number of patient 46, as 4 patients had planned open surgery wit TaTME; One urethral injury occurred during transanal phase; *Excluded 9 patients with stage IV lesion; *Excluded 2 patients with known stage IV lesion
Table 5. Quirke classification for grading the quality of the mesorectum for total mesorectal excisions [44].

<table>
<thead>
<tr>
<th>Complete</th>
<th>Defects</th>
<th>Coning</th>
<th>CRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesorectum</td>
<td>Smooth and intact</td>
<td>Defect is not deeper than 5 mm</td>
<td>None</td>
</tr>
<tr>
<td>Nearly complete</td>
<td>Irregular, moderate bulk</td>
<td>Muscularis propria not visible</td>
<td>Moderate</td>
</tr>
<tr>
<td>Incomplete</td>
<td>Very irregular, little bulk</td>
<td>Defect down to muscularis propria</td>
<td>Moderate to marked</td>
</tr>
</tbody>
</table>

Inadequate visualization, especially during the dissection of the anterior rectal wall may also lead to positive margins and poor oncological outcomes. A down to up approach via TaTME technique may overcome all these challenges faced during laparoscopic rectal surgery. The studies presented in this review paper support the safety and feasibility of TaTME for middle and low rectal adenocarcinomas [33,38-41].

There was an association between shorter operative times and larger number of participants in all studies included in this review. This may be the result of the learning curve necessary to reach a high level of proficiency that comes with a considerable number of surgical cases and the use of two surgical teams approach. Huscher et al. [33], and Veltcamp Helbach et al. [40] reported that, even when a single-team approach is used, TaTME can be accomplished with shorter operative times (median time, 185 - 204 minutes) in comparison to the LapTME (COLOR II trial: median time 240 minutes) [13,33,40]. The conversion rate for TaTME was also quite low (0% to 7.3%) as compared to the rate of 16% observed during LapTME during the COLOR II trial [13]. In addition, intra-operative complication rates for TaTME (2.6%) was significantly lower than 14% observed in patients treated with LapTME or 13% in patients undergoing open TME described in the CLASSIC trial [44]. In addition, a large meta-analysis by Arezzo et al. [45] comparing laparoscopic to open surgery for rectal cancer indicated a mortality rate of 1% for laparoscopic group and 2.4% for open surgery group.

As TaTME is still a relatively new technique, there is a possibility of encountering new and unexpected types of complications during the learning phase. As part of the surgery requires placing purse-string of the rectum, there is an increased risk of peri toneal/pelvic contamination. A study by Vethuis et al. [46] in 2015 showed that 9 out of 23 (39%) patients had positive abdominal cultures after TaTME. Out of these 9 patients, 4 developed presacral abscess with or without anastomotic dehiscence. The impact of perioperative care (e.g., use of preoperative bowel preparation and oral antibiotics, rectal lavage with anti-bacterial solution etc.) on the rate of pelvic abscess formation needs further investigations. Concerns have also been raised in earlier studies regarding urinary morbidity (urethral injury, urinary retention, and infection) after TaTME procedure [15]. However, Tuech et al. [39] indicated that although 5 pts out of 56 (8.9%) experienced urinary retention requiring short-term urethral catheterization, these patients did not experience any long term urinary dysfunction [39]. Another study by Chen et al. [47] who performed TaTME with a trial of expedited Foley removal (on post-operative day 2) did not observe any incidence of urinary dysfunction.

The majority of complications published for TaTME pertain to short-term outcomes (within 30 days). Study regarding functional outcome after TaTME is still quite limited. Tuech et al. [39] did inquire about fecal continence and sexual function after TaTME. Severe fecal incontinence was observed in 5.7% of patients who required the creation of a colostomy, whereas 28% of patients reported difficult stool evacuation. In terms of sexual function, 11.2% of sexually active patients reported severe impotence. Whether TaTME surgery has a significant impact on ileostomy closure rate, anastomotic stricture, fecal continence, or sexual function is still unclear.

The oncological quality of TaTME was also comparable to published data from LapTME or open TME. In COLOR II and CLASSIC trial, completeness of TME was reported to be 66% to 88% for the open surgeries and 77% to 84% for the laparoscopic approach [6,14,44]. In comparison, CRM completeness in TaTME reported by studies included in this review ranged from 72% to 97%. CRM positive status in TaTME study was comparable to the reports from the CLASSIC trial (7% laparoscopic and 5% open approach). Whether the higher quality of mesorectal resection observed in TaTME patients will translate into lower local recurrences and longer survival is uncertain. The range of local recurrence reported by included study in this review was 1.9% to 2.5%, which is lower than 5% reported in COLOR II trial [6].

**Comparative study: TaTME versus LapTME**

Although studies described in this review showed promising results for TaTME in terms of oncological resection quality and short-term outcomes, it is still unclear whether this novel technique is equivalent or superior to LapTME. A small number of comparative studies, mainly composed of matched case-control design, have been published comparing the outcomes of TaTME and LapTME. Recently, Ma et al. performed a meta-analysis on seven studies [48]. Overall, 573 subjects were included with 270 patients treated with TaTME and 303 patients treated with LapTME. Peri-operatively, TaTME group showed 23 minutes shorter operative time (P<0.01) as well as lower conversion rate (OR=0.29, 95% CI=0.11–0.81, P=0.02) as compared to LapTME group while the length of hospital stay showed no difference between the two groups. In the included comparative studies, TaTME had a significantly lower rate of post-operative complications (OR=0.65, 95% CI=0.45–0.95, P=0.03). However, the rate of anastomotic leak, ileus, and urinary morbidity was similar. There was no statistically significant difference in re-admission rates between the groups. TaTME patients showed higher rate of complete mesorectal resection as compared to LapTME (83.4% versus 73.4%, respectively; OR=1.75, 95% CI=1.02–3.01, P=0.04). Additionally, fewer patients had a positive CRM within the TaTME group (OR=0.39, 95% CI=0.17–0.86, P=0.02). There was no statistical difference between TaTME and LapTME in regards to a number of lymph node harvested, length and positivity of distal resection margin. Overall, TaTME, as compared to LapTME,
appears to achieve higher quality of mesorectal excision and comparable post-operative complications, admission length and readmission rates.

**Future considerations**

Selection biases as well as heterogeneity of the quality of surgical instruments are intrinsic to the design of observational studies included in our review. Although there is a clear need for randomized control trials to directly compare the outcomes of TaTME and LapTME, several considerations can be drawn from the current evidence. The first one is that TaTME provides similar oncological outcomes to LapTME and open TME. Second is that TaTME can be performed safely, and with low perioperative morbidity. Although precise indications and contraindications for TaTME have not been established yet, current evidence suggests that TaTME would be most suitable for mid to low rectal cancer in obese/male patients who cannot be treated with local excision. On the other hand, locally advanced tumors (T4), possible tumor invasion in the sphincter, or threatened CRM status will be best served by open surgery.

As TaTME requires expertise in both laparoscopic and transanal techniques, wide implementation may be difficult and a standardized cadaver/animal courses, as well as in-hospital proctoring will be necessary before being adopted by general and colorectal surgeons.

Lastly, cost effectiveness of TaTME still needs to be investigated. The direct upfront cost of TaTME will is higher if a rigid TEMS platform system is utilized as compared to TAMIS. Two-team approach also requires more staff and may also increase the cost of the procedure, although costs may be offset by a shorter operating time. If TaTME can lead to shorter length of stay or lower complication rate, then it may result in indirect cost saving as well. To answer most of these questions, a large randomized controlled study (COLOR III) is underway to compare TaTME to LapTME for treatment of patients with mid and low rectal adenocarcinoma [7].

**Conclusion**

TaTME offers exciting new future for treatment of mid to lower rectal cancer surgery. So far, current studies have shown short-term safety and feasibility of TaTME. Ultimately, randomized control trials and longer follow-ups will be required to prove the oncological safety and effectiveness of TaTME.
References


